Epicardial and subcutaneous fat The protocol was approved by the Ethics Committee of Clinical Research of Galicia
What is the Expected Future
Medications that promote weight gainincluding certain antipsychotics (olanzapine, clozapine), mood stabilizers (valproate, lithium), antidepressants (mirtazapine, paroxetine), corticosteroids, and some diabetes medications (insulin, sulfonylureas, thiazolidinediones)may counteract tirzepatide's weight-reducing effects
The most important mediator in this process is posited to be the expression of the Zif268 gene, which is suggested to be overexpressed in animals exposed to Melanotan 1
In the 68-week STEP 1 trial, adults receiving once-weekly semaglutide 2.4 mg lost an average of 14.9% of their starting body weight, compared with 2.4% among participants receiving placebo
Patients on GLP-1s can experience accelerated changes in facial volume, skin laxity, and body contour, especially when weight loss is brisk